A gender-related action of IFNbeta-therapy was found in multiple sclerosis

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Contasta, Ida ^a   Totaro, Rocco ^b   Pellegrini, Patrizia ^a   Del Beato, Tiziana ^a   Carolei, Antonio ^b   Berghella, Anna Maria ^a  

^a INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Autoimmune diseases; CD30; Clinical biomarkers; Clinical targets; Gender differences; Multiple sclerosis; Th cell networks; Th cytokine networks

Indexed keywords

BETA INTERFERON;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HELPER CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MULTIPLE SCLEROSIS; SEX DIFFERENCE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGEN-PRESENTING CELLS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; HOMEOSTASIS; HUMANS; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-6; MALE; MULTIPLE SCLEROSIS; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, HELPER-INDUCER; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84868681545     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-223     Document Type: Article

References (49)

1. Whitacre CC. Sex differences in autoimmune disease. Nat Immunol 2001, 2:777-780. 10.1038/ni0901-777, 11526384.
2. McCarthy M. The " gender gap" in autoimmune disease. Lancet 2000, 356:1088. 10.1016/S0140-6736(05)74535-9, 11009154.
3. Beageley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol Med Microbiol 2003, 38:13-22. 10.1016/S0928-8244(03)00202-5, 12900050.
4. Gleicher N. Some thoughts on the reproductive autoimmune failure syndrome (RAFS) and TH-1 versus TH-2 immune responses. Am J Reprod Immunol 2002, 48:252-254. 10.1034/j.1600-0897.2002.01111.x, 12516636.
5. Yakoo T, Takakuwa K, Ooki I, Kikuchi A, Tamura M, Tanaka K. Alterations of TH1 and TH2 cells by intracellular cytokine detection in patients with unexplained recurrent abortion before and after immunotherapy with the husband's mononuclear cells. Fertil Steril 2006, 85:1452-1458. 10.1016/j.fertnstert.2005.10.058, 16647376.
6. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
7. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7:145-173. 10.1146/annurev.iy.07.040189.001045, 2523712.
8. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996, 9(4):532-562. 172909, 8894351.
9. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933-944. 10.1038/nri954, 12461566.
10. Zhou L, Chong MM, Littman DR. Plasticity of CD4+T cell lineage differentiation. Immunity 2009, 30:646-655. 10.1016/j.immuni.2009.05.001, 19464987.
11. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007, 25:821-852. 10.1146/annurev.immunol.25.022106.141557, 17201677.
12. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001, 276:37672-37679. 10.1074/jbc.M104521200, 11483607.
13. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21. 10.1038/83713, 11137993.
14. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9:641-649. 10.1038/ni.1610, 2597394, 18454151.
15. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, Soumelis V. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650-657.
16. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008, 454:350-352. 10.1038/nature07021, 2760130, 18469800.
17. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol 2008, 9:1347-1355. 10.1038/ni.1677, 2999006, 18997793.
18. Veldhoen M, Uyttenhove C, van Snick J, Helmby H, Westendorf A, Buer J, Martin B, Wilhelm C, Stockinger B. Transforming growth factor beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008, 9:1341-1346. 10.1038/ni.1659, 18931678.
19. Greer JM, McCombe PA. Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011, 234(1-2):7-18.
20. Polman CH, Miller DH, McDonald WI, Thompson AJ. Treatment recommendations for interferon-beta in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999, 67:561-564. 10.1136/jnnp.67.5.561, 1736631, 10519854.
21. Grigoriadis N. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. Clin Neurol Neurosurg 2002, 104:251-258. 10.1016/S0303-8467(02)00048-3, 12127664.
22. Contasta I, Totaro R, Berghella AM, Pellegrini P, Del Beato T, Carolei A, Adorno D. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNbeta1A treatment in multiple sclerosis patients. Int J Immunopathol Pharmacol 2010, 23(1):213-226.
23. Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis. Neuroimmunomodulation 2005, 12(4):220-234. 10.1159/000085654, 15990453.
24. Berghella AM, Pellegrini P, Del Beato T, Ciccone F, Contasta I. The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy. Cancer Immunol Immunother 2011, 60(10):1373-1381. 10.1007/s00262-011-1068-5, 3176405, 21739118.
25. Bray D. Reasoning for results. Nature 2001, 412(6850):863. 10.1038/35091132, 11528456.
26. Janes KA, Lauffenburger DA. A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006, 10(1):73-80. 10.1016/j.cbpa.2005.12.016, 16406679.
27. Randerson PF. Why do we need multivariate analysis?. Biological Data Analysis. A Pratical Approach 1993, 173. New York, NY, USA: Oxford University Press, Fry JC.
28. Thomson A. The Cytokine Handbook 1994, San Diego, Calif, USA: Academic Press.
29. Banchereau J. Converging and diverging properties of human interleukin-4 and interleukin-10. Behring Inst Mitt 1995, 96:58-77.
30. Cua DJ, Kastelein RA. TGF-β, a " double agent" in the immune pathology war. Nat Immunol 2006, 7(6):557-559. 10.1038/ni0606-557, 16715066.
31. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238. 10.1038/nature04753, 16648838.
32. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol 2010, 88(6):624-631. 10.1038/icb.2010.53, 3090036, 20421880.
33. Pellegrini P, Totaro R, Contasta I, Berghella AM, Russo T, Carolei A, Adorno D. IFNβ1a treatment and reestablishment of Th1 regulation in MS patients: dose effects. Neuropharmacol 2004, 27:258-269.
34. Bloemena E, Roos MT, Van-Heijst JL, Vossen JM, Schellekens PT. Whole blood lymphocyte cultures. J Immunol Methods 1989, 122:161-167. 10.1016/0022-1759(89)90260-3, 2529314.
35. Cohen SBA, Clayton J, Londei M, Feldmann M. T Cells and cytokines. Cytokines 1995, 179. New York: Oxford University Press, Rickwood D, Hames BD, 2.
36. Doyle A, Stein M, Keshavi S, Gordon S. Assays for macrophage activation by cytokines. Cytokines 1995, 269. New York: Oxford University Press, Rickwood D, Hames BD, 2.
37. Berghella AM, Pellegrini P, Piancatelli D, Maccarone D, Del Beato T, Giubilei D, Pomidori A, Adorno D, Casciani CU. Progression mechanisms in colon cancer: soluble interleukin-2 (IL-2) receptor, IL-2 plus anti-CD3 proliferative response and tumour stage correlations. Cancer Immunol Immunother 1994, 38(3):160-166.
38. Azuaje F, Devaux Y, Wagner DR. Coordinated modular functionality and prognostic potential of a heart failure biomarker-driven interaction network. BMC Syst Biol 2010, 12(4):60.
39. Fujita A, Gomes LR, Sato JR, Yamaguchi R, Thomaz CE, Sogayar MC, Miyano S. Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates. BMC Syst Biol 2008, 2(5):10. 2258206, 18234101.
40. Janes KA, Lauffenburger DA. A biological approach to computational models of proteomic networks. Curr Opin Chem Biol 2006, 10(1):73-80. 10.1016/j.cbpa.2005.12.016, 16406679.
41. Gonzalez E, van Liempd S, Conde-Vancells J, Gutierrez-de Juan V, Perez-Cormenzana M, Mayo R, Berisa A, Alonso C, Marquez CA, Barr J, Lu SC, Mato JM, Falcon-Perez JM. Serum UPLC-MS/MS metabolic profiling in an experimental model for acute-liver injury reveals potential biomarkers for hepatotoxicity. Metabolomics 2012, 8:997-1011. 10.1007/s11306-011-0329-9, 3490499, 23139648.
42. Janes KA, Yaffe MB. Data driven modelling of signal transduction networks. Nat Rev 2006, 7:820-828.
43. Pace L, Pioli C, Doria G. IL-4 modulation of CD4+CD25+ T regulatory cell-mediated suppression. J Immunol 2005, 174(12):7645-7653.
44. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8:191-197. 10.1038/ni1428, 17136045.
45. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, Vollmar P, Stritesky GL, Kaplan MH, Waisman A, Kuchroo VK, Oukka M. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008, 105(47):18460-18465. 10.1073/pnas.0809850105, 2587589, 19015529.
46. Nowak EC, Weaver CT, Turner H, Begum-Haque S, Becher B, Schreiner B, Coyle AJ, Kasper LH, Noelle RJ. IL-9 as a mediator of Th17-driven inflammatory disease. J Exp Med 2009, 206:1653-1660. 10.1084/jem.20090246, 2722185, 19596803.
47. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y, Mizuno T, Suzumura A. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011, 186(7):4415-4421. 10.4049/jimmunol.1003307, 21346235.
48. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, Sedgwick JD, Cua DJ. Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957. 10.1084/jem.20030896, 2194162, 14662908.
49. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L. Interleukin-17 production in central nervous system infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155. 10.2353/ajpath.2008.070690, 2189615, 18156204.